Evidence map›Paper›PMID 22679178›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2012

How to develop treatments for biologically heterogeneous "diseases".

Richard M Simon

Abstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Clinical trials in multiple sclerosis: potential future trial designs.Therapeutic advances in neurological disorders · 2019
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Richard M SimonBiometric Research Branch, Division of Cancer Treatment & Diagnosis, National Cancer Institute, Bethesda, Maryland, USA. rsimon@nih.gov

Funding

Intramural NIH HHS Z99 CA999999
6 · The paper itself

Abstract

The standard paradigm for the design of phase III clinical trials is not suitable for evaluation of molecularly targeted treatments in biologically heterogeneous groups of patients. Here, we comment on alternative clinical trial designs and propose a prospective discovery/evaluation framework for using tumor genomics in the design of phase III trials.

Indexed as

Research DesignAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedCarcinoma, Non-Small-Cell LungCetuximabClinical Trials, Phase III as TopicHumansLung NeoplasmsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedCetuximab

Identifiers

PMID22679178
PMCPMC4135717

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.